- Home
- CHPT vs EDIT Comparison
CHPT vs EDIT Comparison
Compare CHPT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | EDIT |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.8M | 202.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CHPT | EDIT |
|---|---|---|
| Price | $7.05 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $12.68 | $4.50 |
| AVG Volume (30 Days) | 544.8K | ★ 1.9M |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,793,000.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.63 | $0.91 |
| 52 Week High | $22.40 | $4.54 |
Technical Indicators
Market Signals| Indicator | CHPT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 39.21 |
| Support Level | $6.84 | $1.99 |
| Resistance Level | $7.19 | $2.28 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 65.38 | 23.08 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.